Amy Tseng, MBA
President & CEO, TissueTech, Inc. & Bio-Tissue, Inc.
An accomplished CPA with experience at both Ernst & Young and Price Waterhouse, Amy founded Bio-Tissue in 1997 with the vision of reintroducing amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy has carried this mission, building Bio-Tissue into the industry leader. Through excellent financial and corporate management, she has guided Bio-Tissue through impressive levels of annual growth. In addition to her instrumental role in founding the company, Amy continues to lead and drive the company not only to provide the highest quality product possible, but also to continuously improve methods of wound care management.
Amy Tseng graduated from the National Taiwan University and received her MBA from the University of Southern California.
Scheffer C. G. Tseng, MD, PhD
Chief Scientific Officer, TissueTech, Inc.
Dr. Scheffer C. G. Tseng co-founded TissueTech and Bio-Tissue with Ms. Amy Tseng in 1997. Dr. Tseng is a world-renowned surgeon in ocular surface reconstruction and a well-published physician scientist with over 300 peer-reviewed clinical and scientific papers. He pioneered limbal stem cell transplantation and popularized the concept of using the CRYOTEK™ process to preserve the natural wound healing properties of amniotic membrane for ocular surface reconstruction. His research focus during the last 10 years has been to identify the active biological components of human amniotic membrane, to develop alternative products in delivering the efficacies of its natural healing properties, and to expand the benefits of its clinical applications.
Dr. Scheffer C. G. Tseng received his M.D. at National Taiwan University and his Ph.D. in Experimental Pathology at the University of California, San Francisco. He completed his residency for Ophthalmology at the Wilmer Eye Institute at Johns Hopkins and his fellowship in Cornea and External Diseases at Massachusetts Eye and Ear Infirmary. Before he joined the Company, he was a Chair Professor at Bascom Palmer Eye Institute, University of Miami School of Medicine.
Chief Financial Officer, TissueTech, Inc.
Michael is an accomplished financial executive with over 25 years of experience in public accounting and public and private corporations. Most recently, he was the CFO of a start-up medical device company he co-founded. Prior to that, Mike was the CFO of Stiefel Laboratories, the largest privately-held dermatology company in the world, before it was acquired by Glaxo Smith Klein in 2009. Mike joined Stiefel in 1999 and rose to the leading position of its global financial operations in 2005. He was an integral member of the executive leadership team providing global strategic and operational direction.
Michael Cornelius received his Bachelor of Science in Business Administration from Indiana University of Pennsylvania, and he is a CPA with a strong international tax background.
Tom Daniells, MBA
Chief Commercial Officer, Bio-Tissue, Inc.
With 28 years of sales, marketing, international and business development experience in ophthalmology, Tom has a wealth of knowledge about our industry. He started his career at Alcon Surgical, in which he progressively climbed the leadership ladder. Eight years ago, Tom joined Optos, a smaller and high-growth company, as the Director of Sales and then moved into the VP Marketing role. With Tom’s intimate involvement, the company grew from less than $10 million to over $140 million. Moreover, in his last role as Vice President of Business Development at Optos, Tom led the acquisition of two companies, including Opko Health, Inc.
Tom Daniells received his Bachelor of Science in Business Administration and Marketing from California State University in Fresno and an MBA with an emphasis on international marketing from the University of California, Irvine.